Drugs & medicalClass I

Hikma Injectables USA Inc recalls Phenylephrine in 0.9% Sodium Chloride Injection Preservative Free, 100mcg/mL, 5mL syringe, Rx only, Hikma Injectables USA Inc, 36…

Labeling: Label mix-up - ephedrine syringes mislabeled as phenylephrine.

Read the official notice →
Date
2024-05-29
Country
United States
Brand
Hikma Injectables
Product
Phenylephrine in 0.9% Sodium Chloride Injection Preservative Free, 100mcg/mL, 5mL syringe, Rx only, Hikma Injectables USA Inc, 36 Stults…
Classification
Class I
Units
CO, GA, PA, SD, WA
Category
Drugs & medical
Source
FDA · Drug

Copied automatically from the US Food and Drug Administration. Details may be shortened or out of date; the official notice is the authoritative source. Disclaimer

What to do

  1. Check the product name, strength and lot number against the official notice.
  2. Do not stop a prescribed medicine without talking to your doctor or pharmacist first.
  3. Ask the pharmacy or supplier about a replacement or refund.

General guidance from Recall Atlas. The official notice from the US Food and Drug Administration has the exact models, batch codes and remedy, and it takes priority.

More Hikma Injectables recalls

  1. 2025-01-08
  2. US
    Drugs & medicalClass II

    Hikma Injectables USA Inc recalls ketamine inj 50 mg per 1 mL, Rx Only, 1 mL fill in a 3mL pre-filled syringe, For IV or IM Use, Hikma Injectables USA Inc., 36 Stults…

    Lack of Assurance of Sterility: The tamper-evident seal on several of the syringes are not attached upon receipt of shipment.

    FDA · DrugHikma Injectables USA IncNationwide in the USAOfficial notice →
  3. 2024-05-08
  4. US
All 3 Hikma Injectables recalls →

Other drugs & medical recalls in the United States

  1. 2024-05-29
  2. US
    Drugs & medicalClass II

    YAMAHA MOTOR CORPORATION recalls Optical Inspection System, YSi series, YRi series. Affected models: YSi-V, YSi-V(HS2), YRi-V

    Non-medical laser products which were determined to not be in compliance with 21 C.F.R. ¿ 1010.2 in that they currently do not bear the required certification label.

    FDA · DeviceYAMAHA MOTOR CORPORATIONUS NationwideOfficial notice →
  3. US
    Drugs & medicalClass I

    Philips Respironics, Inc. recalls BiPAP V30 Auto Ventilator, Part Number 1111178

    Potential for devices to experience interruption/loss of therapy during a Ventilator Inoperative alarm. This may lead to hypoventilation, mild to severe hypoxemia, hypercarbia, respiratory failure/insufficiency, or…

    FDA · DevicePhilips Respironics, Inc.Worldwide distribution. US Nationwide including PR and GU; Austria, Belgium,…Official notice →
  4. US
    Drugs & medicalClass I

    OptumHealth Care Solutions LLC recalls Optum Nimbus II Plus, Model number AAA-00170; Ambulatory Infusion Pump

    Nimbus II Plus, Infusion Pump Systems, manufactured by InfuTronix, are being removed the from the market due to multiple potential failure modes, including battery failure, upstream occlusion, system errors, drug…

    FDA · DeviceOptumHealth Care Solutions LLCUS Nationwide DistributionOfficial notice →
  5. US
    Drugs & medicalClass II

    American Regent, Inc. recalls Vasopressin Injection, USP, 200 Units per 10 mL (20 Units per mL), 10 mL Multiple-Dose Vial, Rx only, For Intravenous Infusion, American…

    Subpotent product in addition to having out-of-specification results for impurities.

    FDA · DrugAmerican Regent, Inc.USA NationwideOfficial notice →
  6. US
    Drugs & medicalClass II

    SOMERSET THERAPEUTICS LLC recalls Haloperidol decanoate Injection 50mg/mL, packaged in a) 1 mL Single-Dose Vials (NDC 70069-381-01) and b) 10 1mL Single-Dose Vials (NDC…

    Presence of Foreign Substance: This oil based product may contain trace amounts of water for injection (WFI).

    FDA · DrugSOMERSET THERAPEUTICS LLCNationwide within the United StatesOfficial notice →
  7. US
    Drugs & medicalClass II

    Preferred Pharmaceuticals, Inc. recalls Duloxetine Delayed-Release Cap USP 30mg, 30-count bottle, Rx only, Preferred Pharmaceutcals, Inc., NDC 68788-9301-03

    CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

    FDA · DrugPreferred Pharmaceuticals, Inc.Product distributed to CA, FL, OK, KS and CTOfficial notice →
See all drugs & medical recalls →